Article Text

PDF
Effect size in CANTOS trial
  1. Nanda Gamad,
  2. Nusrat Shafiq,
  3. Samir Malhotra
  1. Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
  1. Correspondence to Dr Samir Malhotra, Post Graduate Institute Medical Education and Research, Chandigarh 160012, India; smal.pgi{at}gmail.com

Statistics from Altmetric.com

The primary endpoint in Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial published by Ridker et al 1 was non-fatal myocardial infarction, non-fatal stroke or cardiovascular death. The authors concluded that canakinumab 150 mg reduced primary event rates compared with placebo (3.86 vs 4.11 per 100 person-years) with HR 0.85 (95%CI 0.74 to 0.98; P=0.021). Sample …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.